Adalvo Acquires Branded Pain Product Onsolis

Amneal Acquires Saol Therapeutics' Baclofen Franchise

January 5, 2022

Pharmaceuticals

Amneal Pharmaceuticals has agreed to acquire Saol Therapeutics' Baclofen franchise, including Lioresal and LYVISPAHTM, for approximately $83.5 million in cash plus certain low double-digit royalties. The deal expands Amneal's neurology and specialty portfolio, adds institutional commercial infrastructure ahead of its planned biosimilars launches, and is expected to be accretive to Amneal's 2022 adjusted EBITDA and EPS.

JanOne Inc. Agrees to Acquire Soin Therapeutics LLC

September 16, 2022

Pharmaceuticals

JanOne Inc. has executed a term sheet to acquire Soin Therapeutics LLC and its patent-pending low-dose naltrexone formulation (to be named JAN123) for the treatment of Complex Regional Pain Syndrome (CRPS). The deal is valued at $13 million up front with up to $17 million in additional contingent payments (total up to $30 million); JanOne expects to advance JAN123 into GMP manufacturing and file an IND in 2023.

Altavant Sciences Acquires Onspira Therapeutics

January 8, 2020

Biotechnology

Altavant Sciences has acquired Onspira Therapeutics, adding OSP-101 — an inhaled interleukin-1 receptor antagonist with orphan drug designation for bronchiolitis obliterans syndrome (BOS) — to its rare respiratory disease pipeline. The deal closed with upfront and milestone payments to Onspira's shareholders and expands Altavant's capabilities in pulmonary transplant-related therapeutics.

Oragenics Acquires Odyssey Health Neurological Drug Assets

January 2, 2024

Pharmaceuticals

Oragenics, Inc. completed the acquisition of Odyssey Health, Inc.'s neurological drug therapy assets, including ONP-002, ONP-001 rights, a proprietary intranasal delivery device and related formulations. Odyssey retained its remaining assets and operations; Michael Redmond (former Odyssey CEO) was named President of Oragenics to oversee integration and advancement of the neurology pipeline as Oragenics prepares for Phase 2 studies of ONP-002.

Supernus Pharmaceuticals Acquires Adamas Pharmaceuticals

October 11, 2021

Pharmaceuticals

Supernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals in a cash tender offer valued at approximately $400 million upfront plus up to $50 million in contingent value rights, for total consideration of about $450 million. The acquisition gives Supernus two marketed CNS products (GOCOVRI and Osmolex ER), diversifies its Parkinson’s disease portfolio and is expected to be accretive with material synergies in 2022.

Indivior Acquires Opiant Pharmaceuticals

November 14, 2022

Pharmaceuticals

Indivior PLC will acquire Opiant Pharmaceuticals, Inc. for $20.00 per share in cash (approximately $145 million aggregate) plus up to $8.00 per share in contingent value rights tied to OPNT003 revenue milestones. The acquisition strengthens Indivior's addiction-treatment portfolio by adding Opiant's OPNT003 intranasal opioid overdose candidate and earlier-stage pipeline assets, and is expected to be accretive after the second full year of OPNT003 launch.